Vertex Pharmaceuticals Incorporated vs Vanguard Ultra Short Bond ETF — how do they compare? Vertex Pharmaceuticals Incorporated trades at $481.09 (market cap $121.95B), while Vanguard Ultra Short Bond ETF trades at $49.71. The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| VRTX | VUSB | |
|---|---|---|
Market Cap | $121.95B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $529.59 | $50.03 |
52-Week Low | $366.54 | $49.60 |
Enterprise Value | $116.69B | — |
Trailing returns across standard periods
Latest headlines on both assets
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →